Our present results show that Wnt5a expression is a marker of favourable outcome also in premenopausal breast cancer patients and that it is a particularly valuable prognostic marker and thus a possible therapeutic target in pre-menopausal breast cancer patients with ER+ tumors. The gene discussed is WNT5A; the disease is breast cancer.